摘要
目的探讨重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病的临床疗效及安全性。方法在患儿家属知情同意下,采用随机、对照的临床试验设计,将375例小儿呼吸道病毒感染性疾病患儿分为250例治疗组和125例对照组,除常规治疗外,治疗组加用重组人干扰素α-1b雾化治疗,对照组加用利巴韦林雾化治疗;并且对治疗组中的240例患儿治疗前后红细胞、血小板、尿粪常规、肝肾功能、心肌酶的结果进行对比分析。结果共有357例纳入统计,其中治疗组240例,对照组117例,在发热、咽痛、咳嗽、喘憋、肺部啰音消失时间,住院日及治疗有效率等方面,治疗组与对照组比较差异均有统计学意义(P<0.01);且1个疗程后,治疗组除7例病毒性肺炎患儿心肌酶升高外,240例患儿其他各项指标均未发现异常,且用药过程中未见明显不良反应。结论重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病安全有效,方法简单,值得临床推广。
Objective To explore the clinical efficacy and safety of recombinant human interferon α-1b in atomization treatment of pediatric respiratory viral infection. Methods Under the informed consent premise of parents, a random, case-control study was conducted, 375 children with respiratory viral infection were divided into treatment group （250 children） and control group （125 children）, the children in treatment group were treated by atomization treatment of recombinant human interferon α-1b combined with conventional therapy ; the children in control group were treated with atomization treatment of ribavirin combined with conventional therapy. The detection results of red blood cells, platelet, urine and stool routine test, liver function and renal function test, and myocardial enzymes before and after treatment among 240 children in treatment group were compared and analyzed. Results A total of 357 children were enrolled in this study, including 240 children in treatment group and 117 children in control group ; there were statistically significant differences in the disappearance time of fever, sore throat, cough, wheezing, pulmonary rales, the days of hospitalization, and the effective rate between the treatment group and control group （P〈0. 01 ） ; after one course of treatment, except seven children with increase of myocardial enzymes, the other children in treatment group were found with normal indexes, and no obvious adverse reactions were found in the course of treatment. Conclusion Recombinant human interferon α-1b is safe, effective, and simple in treatment of pediatric respiratory viral infection, which is worthy of clinical popularization.
出处
《中国妇幼保健》
CAS
2015年第31期5387-5389,共3页
Maternal and Child Health Care of China
基金
河南省卫生厅科研项目基金〔201203111〕
